Arrowstreet Capital
KZR

Arrowstreet Capital’s Kezar Life Sciences KZR Stock Holding History

Arrowstreet Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,820
Closed -$252K – 2386
2020
Q4 		$252K Sell
4,820
-4,807
-50% -$267K ﹤0.01% 2156
2020
Q3 		$466K Sell
9,627
-43
-0.4% -$2.06K ﹤0.01% 2040
2020
Q2 		$501K Buy
+9,670
New +$488K ﹤0.01% 1964

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Arrowstreet Capital's KZR Position: Q1 2021 in Review

Arrowstreet Capital sold out of Kezar Life Sciences (KZR) in Q1 2021, closing a stake of 4,820 shares — an estimated $252K sold.

Arrowstreet Capital first reported a position in KZR in Q2 2020 and held it in 3 quarters. The position peaked at $501K in Q2 2020. 83 funds tracked by Wall St. Rank hold KZR as of Q1 2021.

  • Arrowstreet Capital reported no remaining Kezar Life Sciences position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 4,820 Kezar Life Sciences shares in Q1 2021, an estimated $252K.
  • Arrowstreet Capital first reported a position in Kezar Life Sciences in Q2 2020 and held it in 3 quarters.
  • Arrowstreet Capital's Kezar Life Sciences position peaked at $501K in Q2 2020.
  • 83 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.